Journal of Hematology & Oncology

Article	Citations
1-year survival in haemophagocytic lymphohistiocytosis: a nationwide cohort study from England 2003–2018	492
Novel natural killer cell-based therapies for hematologic and solid malignancies: latest updates from ASCO 2024	486
The small inhibitor WM-1119 effectively targets KAT6A-rearranged AML, but not KMT2A-rearranged AML, despite shared KAT6 genetic dependency	484
HRAS is a therapeutic target in malignant chemo-resistant adenomyoepithelioma of the breast	471
Identification of restrictive molecules involved in oncolytic virotherapy using genome-wide CRISPR screening	465
Retraction Note: m6A mRNA methylation initiated by METTL3 directly promotes YAP translation and increases YAP activity by regulating the MALAT1-miR-1914-3p-YAP axis to induce NSCLC drug resistance and	407
Mapping the cell therapy landscape: insights into clinical trials and regulatory advances in China	392
WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associ	363
KRAS mutation detection by liquid biopsy for pancreatic ductal adenocarcinoma	356
The Association of Agent Orange Exposure with the progression of monoclonal gammopathy of undetermined significance to multiple myeloma: a population-based study of Vietnam War Era Veterans	338
Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial	330
Comprehensive molecular characterization of lung tumors implicates AKT and MYC signaling in adenocarcinoma to squamous cell transdifferentiation	305
Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies	303
CAR-T therapy alters synthesis of platelet-activating factor in multiple myeloma patients	290
Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy	280
Proteasome inhibition enhances oncolytic reovirus therapy in multiple myeloma independently of its direct cytotoxic effects	277
Cancer vaccines: current status and future directions	276
Landscape of biallelic DNMT3A mutant myeloid neoplasms	261
Evidence of SARS-CoV-2 spike protein on retrieved thrombi from COVID-19 patients	256
Modulating tumor infiltrating myeloid cells to enhance bispecific antibody-driven T cell infiltration and anti-tumor response	248
Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2	233
Integrated proteogenomic analysis revealed the metabolic heterogeneity in noncancerous liver tissues of patients with hepatocellular carcinoma	227
Comparative analysis of cancer cell responses to targeted radionuclide therapy (TRT) and external beam radiotherapy (EBRT)	221
Personalized nanovaccines for treating solid cancer metastases	219
Overcome the challenge for intratumoral injection of STING agonist for pancreatic cancer by systemic administration	214

NBAS, a gene involved in cytotoxic degranulation, is recurrently mutated in pediatric hemophagocytic lymphohistiocytosis	213
Super-enhancer hijacking LINC01977 promotes malignancy of early-stage lung adenocarcinoma addicted to the canonical TGF-β/SMAD3 pathway	193
Targeting CD47 for cancer immunotherapy	187
Efficacy and safety of CPX-351 versus 7 + 3 chemotherapy by European LeukemiaNet 2017 risk subgroups in older adults with newly diagnosed, high-risk/secondary AML: post hoc analysis of a randomized, p	184
Long noncoding RNA Smyca coactivates TGF-β/Smad and Myc pathways to drive tumor progression	180
Hypoxia-induced exosomal circPDK1 promotes pancreatic cancer glycolysis via c-myc activation by modulating miR-628-3p/BPTF axis and degrading BIN1	177
Cancer-associated fibroblast-specific lncRNA LINC01614 enhances glutamine uptake in lung adenocarcinoma	164
Ferroptosis: principles and significance in health and disease	163
Epigenetic regulation of diverse cell death modalities in cancer: a focus on pyroptosis, ferroptosis, cuproptosis, and disulfidptosis	163
Hypertension and incident cardiovascular events after next-generation BTKi therapy initiation	161
Toll-like receptors and toll-like receptor-targeted immunotherapy against glioma	160
A novel lncRNA ROPM-mediated lipid metabolism governs breast cancer stem cell properties	159
IL-15-secreting CAR natural killer cells directed toward the pan-cancer target CD70 eliminate both cancer cells and cancer-associated fibroblasts	159
Recent advances in therapeutic strategies for non-small cell lung cancer	155
Outcomes of patients with acute myeloid leukemia and bone marrow fibrosis	154
Similar outcomes following non-first-degree and first-degree related donor haploidentical hematopoietic cell transplantation for acute leukemia patients in complete remission: a study from the Global	152
Correction: The long and short non-coding RNAs modulating EZH2 signaling in cancer	149
Unraveling the roles and mechanisms of mitochondrial translation in normal and malignant hematopoiesis	146
Targeted degradation of extracellular proteins: state of the art and diversity of degrader designs	139
Identifying long-term survivors and those at higher or lower risk of relapse among patients with cytogenetically normal acute myeloid leukemia using a high-dimensional mixture cure model	139
Small RNA modifications: regulatory molecules and potential applications	137
The developing landscape of combinatorial therapies of immune checkpoint blockade with DNA damage repair inhibitors for the treatment of breast and ovarian cancers	136
Non-invasive diagnosis of esophageal cancer by a simplified circulating cell-free DNA methylation assay targeting OTOP2 and KCNA3: a double-blinded, multicenter, prospective study	134
3D chromatin architecture and transcription regulation in cancer	132
Emerging strategies in targeting tumor-resident myeloid cells for cancer immunotherapy	131
Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient?	129
Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation	127
Kynurenine derivative 3-HAA is an agonist ligand for transcription factor YY1	125
Treatment with soluble CD24 attenuates COVID-19-associated systemic immunopathology	124
Therapeutic roles of mesenchymal stem cell-derived extracellular vesicles in cancer	123
Development of a novel combined nomogram model integrating deep learning-pathomics, radiomics and immunoscore to predict postoperative outcome of colorectal cancer lung metastasis patients	120
First-in-human phase I study of CLL-1 CAR-T cells in adults with relapsed/refractory acute myeloid leukemia	119
Recent advances in targeted strategies for triple-negative breast cancer	118
Osteosarcoma with cell-cycle and fibroblast growth factor genomic alterations: case report of Molecular Tumor Board combination strategy resulting in long-term exceptional response	117
Development and validation of the post-CAR prognostic index for large B-cell lymphoma patients after CAR-T progression in third or later line treatment	117
A single-cell transcriptomic map of the murine and human multiple myeloma immune microenvironment across disease stages	117
Recent advances in sarcoma therapy: new agents, strategies and predictive biomarkers	115
Correction: Non-invasive diagnosis of esophageal cancer by a simplified circulating cell-free DNA methylation assay targeting OTOP2 and KCNA3: a double-blinded, multicenter, prospective study	111
COVID-19 in pediatric cancer patients is associated with treatment interruptions but not with short-term mortality: a Polish national study	110
A single-cell and spatially resolved atlas of human osteosarcomas	109
hUC-EVs-ATO reduce the severity of acute GVHD by resetting inflammatory macrophages toward the M2 phenotype	109
Asciminib add-on to imatinib demonstrates sustained high rates of ongoing therapy and deep molecular responses with prolonged follow-up in the ASC4MORE study	109
Genotype–phenotype associations within the Li-Fraumeni spectrum: a report from the German Registry	108
Treatment outcomes for newly diagnosed, treatment-naïve TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis	107
A proteolysis-targeting chimera molecule selectively degrades ENL and inhibits malignant gene expression and tumor growth	107
Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure	107
Novel potent molecular glue degraders against broad range of hematological cancer cell lines via multiple neosubstrates degradation	106
Methyltransferase-like proteins in cancer biology and potential therapeutic targeting	105
GAS6-based CAR-T cells exhibit potent antitumor activity against pancreatic cancer	105
LCN2 secreted by tissue-infiltrating neutrophils induces the ferroptosis and wasting of adipose and muscle tissues in lung cancer cachexia	104

Deciphering mechanisms of immune escape to inform immunotherapeutic strategies in multiple myeloma	104
Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies	100
Targeting cuproptosis for cancer therapy: mechanistic insights and clinical perspectives	99
Fibrinogen-like protein 1 (FGL1): the next immune checkpoint target	99
Proteasome inhibition enhances the anti-leukemic efficacy of chimeric antigen receptor (CAR) expressing NK cells against acute myeloid leukemia	98
Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts	98
HLA alleles associated with asparaginase hypersensitivity in Chinese children	96
Chemo-free treatment of adult patients with Ph-positive acute lymphoblastic leukemia: latest updates from the 2023 ASH annual meeting	96
Preclinical evaluation of combination nemtabrutinib and venetoclax in chronic lymphocytic leukemia	93
Correction: Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee	93
Circular RNAs: characteristics, biogenesis, mechanisms and functions in liver cancer	92
Metabolic landscapes in sarcomas	92
Electrostatic anti-CD33-antibody–protamine nanocarriers as platform for a targeted treatment of acute myeloid leukemia	90
Innate immune mediator, Interleukin-1 receptor accessory protein (IL1RAP), is expressed and pro-tumorigenic in pancreatic cancer	90
The functional and clinical roles of liquid biopsy in patient-derived models	88
Targeting Claudin-18.2 for cancer therapy: updates from 2024 ASCO annual meeting	87
Prognostic and therapeutic implications of measurable residual disease in acute myeloid leukemia	87
Iparomlimab (QL1604) in patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) unresectable or metastatic solid tumors: a pivotal, single-arm, multicenter, phase II	87
Echinomycin as a promising therapeutic agent against KSHV-related malignancies	84
Worked to the bone: antibody-based conditioning as the future of transplant biology	84
JMJD4-demethylated RIG-I prevents hepatic steatosis and carcinogenesis	84
A clinical study of autologous chimeric antigen receptor macrophage targeting mesothelin shows safety in ovarian cancer therapy	83
C3G promotes bone marrow adipocyte expansion and hematopoietic regeneration after myeloablation by enhancing megakaryocyte niche function	83
LncRNA Snhg6 regulates the differentiation of MDSCs by regulating the ubiquitination of EZH2	82
Tucidinostat plus pediatric-inspired chemotherapy for newly diagnosed adult ETP-ALL/LBL: a single-arm, phase 2 trial	82
The roles of GTPase-activating proteins in regulated cell death and tumor immunity	82
CD20 xCD3 bispecific antibodies for large B cell lymphoma: latest updates from 2024 ASH annual meeting	82
Cancer-associated fibroblast heterogeneity is associated with organ-specific metastasis in pancreatic ductal adenocarcinoma	80
Gastric cancer treatment: recent progress and future perspectives	79
Challenges and new technologies in adoptive cell therapy	79
Clinical experiences with venetoclax and other pro-apoptotic agents in lymphoid malignancies: lessons from monotherapy and chemotherapy combination	79
New immunotherapy strategies for patients with sarcomas: highlights from the 2023 ASCO annual meeting	78
Intratumor heterogeneity: the hidden barrier to immunotherapy against MSI tumors from the perspective of IFN-γ signaling and tumor-infiltrating lymphocytes	75
Lenvatinib and immune-checkpoint inhibitors in hepatocellular carcinoma: mechanistic insights, clinical efficacy, and future perspectives	74
Targeting extracellular matrix stiffness and mechanotransducers to improve cancer therapy	73
Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives	72
The long and short non-coding RNAs modulating EZH2 signaling in cancer	69
Long-term survival with donor CD19 CAR-T cell treatment for relapsed patients after allogeneic hematopietic stem cell transplantation	67
GVHD occurrence does not reduce AML relapse following PTCy-based haploidentical transplantation: a study from the ALWP of the EBMT	67
Genomic characterization of AML with aberrations of chromosome 7: a multinational cohort of 519 patients	66
Targeting regulated cell death (RCD) with small-molecule compounds in triple-negative breast cancer: a revisited perspective from molecular mechanisms to targeted therapies	66
m6A regulators as predictive biomarkers for chemotherapy benefit and potential therapeutic targets for overcoming chemotherapy resistance in small-cell lung cancer	66
Targeting GPRC5D for multiple myeloma therapy	66
Reduced-dose chemotherapy and blinatumomab as induction treatment for newly diagnosed Ph-negative B-cell precursor acute lymphoblastic leukemia: a phase 2 trial	66
First-in-human phase I/Ib study of QL1706 (PSB205), a bifunctional PD1/CTLA4 dual blocker, in patients with advanced solid tumors	66
RAS signaling in carcinogenesis, cancer therapy and resistance mechanisms	65
Amplification of spatially isolated adenosine pathway by tumor–macrophage interaction induces anti-PD1 resistance in hepatocellular carcinoma	64
SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disorders	63
LncRNA-PACERR induces pro-tumour macrophages via interacting with miR-671-3p and m6A-reader IGF2BP2 in pancreatic ductal adenocarcinoma	63
Applications of single-cell sequencing in cancer research: progress and perspectives	61
Metabolic reprogramming in the tumor microenvironment of liver cancer	61
Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation	60
METTL16 promotes liver cancer stem cell self-renewal via controlling ribosome biogenesis and mRNA translation	60
Mesenchymal stem/stromal cells in cancer therapy	60
Correction: Immunosenescence: a key player in cancer development	60
Universal immunotherapeutic strategy for hepatocellular carcinoma with exosome vaccines that engage adaptive and innate immune responses	60
Homogeneously high expression of CD32b makes it a potential target for CAR-T therapy for chronic lymphocytic leukemia	59
Broadly applicable TCR-based therapy for multiple myeloma targeting the immunoglobulin J chain	59
Large-scale real-life analysis of survival and usage of therapies in multiple myeloma	58
Correction: Large-scale real-life analysis of survival and usage of therapies in multiple myeloma	57
Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study	56
Considerations for the design of antibody drug conjugates (ADCs) for clinical development: lessons learned	56
Blockade of checkpoint receptor PVRIG unleashes anti-tumor immunity of NK cells in murine and human solid tumors	56
Correction : LINC01123, a c-Myc-activated long non-coding RNA, promotes proliferation and aerobic glycolysis of non-small cell lung cancer through miR-199a-5p/c-Myc axis	56
Treatment of myelodysplastic syndromes in the era of precision medicine and immunomodulatory drugs: a focus on higher-risk disease	55
Momelotinib: an emerging treatment for myelofibrosis patients with anemia	55
Nanomaterials-driven in situ vaccination: a novel frontier in tumor immunotherapy	54
Replicon RNA vaccines: design, delivery, and immunogenicity in infectious diseases and cancer	54
Elevated plasma levels of IL-6 and MCP-1 selectively identify CML patients who better sustain molecular remission after TKI withdrawal	54
Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee	53
Mesenchymal stromal cells plus basiliximab, calcineurin inhibitor as treatment of steroid-resistant acute graft-versus-host disease: a multicenter, randomized, phase 3, open-label trial	53
Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study	52
Advances in targeting histone deacetylase for treatment of solid tumors	52
The cGAS‒STING pathway in cancer immunity: mechanisms, challenges, and therapeutic implications	51
A practical approach on the classifications of myeloid neoplasms and acute leukemia: WHO and ICC	51
Circular RNA circHERC4 as a novel oncogenic driver to promote tumor metastasis via the miR-556-5p/CTBP2/E-cadherin axis in colorectal cancer	51
Emerging strategies to target RAS signaling in human cancer therapy	50
Precision oncology in AML: validation of the prognostic value of the knowledge bank approach and suggestions for improvement	49
Safety and efficacy of amulirafusp alfa (IMM0306), a fusion protein of CD20 monoclonal antibody with the CD47 binding domain of SIRPα, in patients with relapsed or refractory B-cell non-Hodgkin lympho	49
Advances in CAR-T cell therapy for hematologic and solid malignancies: latest updates from 2024 ESMO Congress	49

Retraction Note: AMLnet, A deep-learning pipeline for the differential diagnosis of acute myeloid leukemia from bone marrow smears	49
High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status	49
Immune checkpoint of B7-H3 in cancer: from immunology to clinical immunotherapy	49
Myeloid-like tumor hybrid cells in bone marrow promote progression of prostate cancer bone metastasis	49
Correction to: HLA-A2.1-restricted ECM1-derived epitope LA through DC cross-activation priming CD8+ T and NK cells: a novel therapeutic tumour vaccine	49